[Effectiveness of using cefuroxime in the obstetrics and gynecology clinic].
The clinical trials of cefuroxim in the treatment of patients with various postnatal diseases and postoperative complications caused by Staph. aureus, E. coli, Klebsiella or Proteus showed its high efficacy. No adverse reactions of the drug were observed in any of 24 patients. The drug was rapidly absorbed on its intramuscular administration. Its therapeutic concentrations in the blood, milk and urine persisted for 8 hours after a single administration. Cefuroxim may be recommended for the treatment of patients with moderately severe infections. The single dose is 750 mg administered every 8 hours. However, in patients with severe postoperative complications cefuroxim should be used in combination with antibiotics preventing directed selection of the microorganisms resistant to cefuroxim (nonsporulating anaerobic bacteria, Ps. aeruginosa).
D001424:Bacterial Infections / Q000188:drug therapy*; D002444:Cefuroxime / Q000378:metabolism / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004341:Drug Evaluation; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy; D008413:Mastitis / Q000188:drug therapy; D008826:Microbial Sensitivity Tests; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011645:Puerperal Infection / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy
D002511:Cephalosporins; D002444:Cefuroxime
Effektivnost' primeneniia tsefuroksima v akushersko-ginekologicheskoĭ klinike.